This Phase 2 randomized trial looked at a treatment for patients with advanced non-small cell lung cancer. The study included 98 people who had high levels of PD-L1 and were in stage IIIB or IV disease. Participants were randomly assigned to receive either a combination of domvanalimab and zimberelimab with chemotherapy, zimberelimab with chemotherapy, or chemotherapy alone.
The main result measured how long patients lived without their cancer getting worse. The combination of domvanalimab and zimberelimab showed a longer time without progression compared to zimberelimab alone. The combination also showed a longer time without progression compared to chemotherapy alone. However, the confidence intervals for these comparisons included the possibility of no difference.
Overall survival and response rates were also measured. The combination therapy did not reach a final survival endpoint during the study follow-up. Response rates were slightly higher for the combination therapy than for the other groups. Safety data showed that serious side effects were reported less often with the new drugs than with chemotherapy alone. No new safety concerns were identified.
